 Home > Medical News > Latest Medical News > Pfizer's ulcerative colitis drug etrasimod successful in phase 3 trial

Pfizer's ulcerative colitis drug etrasimod successful in phase 3 trial

 Last Update: 2022-04-23
 Source: Internet
 Author: User

Tags

ny new hampshire

k4 drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

On March 23, Pfizer said that etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator obtained from its $6.

Results of a clinical study called Elevate12 showed that patients taking etrasimod had a significantly higher rate of symptom relief after 12 weeks of treatment than patients receiving placebo

At present, the full analysis results of the study have not been released to the public, and Pfizer will present the complete data of etrasimod at a future academic conference

On March 11, Pfizer announced that it has completed the acquisition of Arena, acquiring all outstanding shares of Arena for $100 per share in cash, and at the same time, Arena's common stock will be delisted from the Nasdaq market

According to Evaluate Pharma, etrasimod sales are expected to reach $909 million by 2026, of which 54% will be contributed by ulcerative colitis

In a previous phase II study of ulcerative colitis, etrasimod demonstrated efficacy in achieving clinical response, clinical remission, or endoscopic improvement in a large number of patients

Reference source:

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.